ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
An increase in cardiac biomarkers has been shown to occur in 5% to 30% of patients after
otherwise successful percutaneous coronary interventions (PCIs)(1) Apart from side-branch
occlusion, intimal dissection and coronary spasm, a possible aetiology of myonecrosis after
PCI might be distal embolization of atherogenic materials from plaque disruption,(2 )causing
obstruction of blood flow at capillary level resulting in micro-infarction.(3,4 )Recent
studies have suggested that pretreatment with Atorvastatin may be associated with a reduction
in infarct size after elective PCI. (5-7 ). Actually the standard pretreatment in patients
undergoing elective coronary-PCI and already treated with aspirin is clopidogrel loading dose
administration before procedure.(8,9)The investigators compared a high (80mg) re-loading dose
of Atorvastatin with a high loading dose of Rosuvastatin (40 mg) both administered within 24h
before the procedure in reducing the rate of periprocedural MI. Therefore, the investigators
will conduct a single center, prospective randomized study to assess whether a single, high
(80mg) loading (within 24h)dose of Atorvastatin compared with a single loading dose of
Rosuvastatin (20 mg) is effective in preventing elevation of biomarkers of MI after elective
coronary stent implantation. We evaluate the incidence of MACCE(occurring of cardiac death,
myocardial infarction (including periprocedural myonecrosis) and stroke at 30 days 6 and 12
month follow-up.